Cargando…
Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor
PURPOSE: To evaluate the effect and immune response of transcatheter arterial embolization (TAE) combined with donafenib in rabbit VX2 liver tumor model. MATERIALS AND METHODS: Thirty-six New Zealand white rabbits with VX2 liver tumor were randomly divided into three groups. The LD group was treated...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434853/ https://www.ncbi.nlm.nih.gov/pubmed/34522137 http://dx.doi.org/10.2147/CMAR.S328294 |
_version_ | 1783751691145838592 |
---|---|
author | Shi, Qin Li, Tongqiang Huang, Songjiang Bai, Yaowei Wang, Yingliang Liu, Jiacheng Zhou, Chen Chen, Yang Xiong, Bin |
author_facet | Shi, Qin Li, Tongqiang Huang, Songjiang Bai, Yaowei Wang, Yingliang Liu, Jiacheng Zhou, Chen Chen, Yang Xiong, Bin |
author_sort | Shi, Qin |
collection | PubMed |
description | PURPOSE: To evaluate the effect and immune response of transcatheter arterial embolization (TAE) combined with donafenib in rabbit VX2 liver tumor model. MATERIALS AND METHODS: Thirty-six New Zealand white rabbits with VX2 liver tumor were randomly divided into three groups. The LD group was treated with the emulsion of 0.5 mL lipiodol and 4 mg donafenib via hepatic arterial administration. The LE group was treated with the emulsion of 0.5 mL lipiodol and 4 mg epirubicin. The control group was treated with the equal volume of saline. Four rabbits were euthanized in each group on day 1, 3 and 7 after treatment. The tumor growth, histological markers associated with angiogenesis and immune response were assessed by imaging and histopathology. In addition, immune modulatory cytokines included interleukin (IL)-6, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and biochemical hepatorenal function were measured. RESULTS: Compared to other groups, LD group achieved lower tumor growth rate, fewer metastatic lesions, and higher tumor necrosis rate on day 7 after treatment. The percentage of CD31-positive area in the LD group was significantly lower than that in the LE group on day 3 and 7 after treatment. In addition, CD8(+) lymphocytes infiltration was more pronounced in LD group than in LE group on day 7 after treatment, regardless of in the tumor or adjacent liver tissue. Serum cytokines including IL-6, TNF-α and IFN-γ were strongly upregulated in the LD group on day 1 after treatment. And there was no significant difference in the hepatorenal function between LD group and LE group after treatment. CONCLUSION: The combination of TAE and angiogenesis inhibitor donafenib resulted in a potentiated tumoricidal effect, anti-angiogenesis and antitumour T cell response in rabbit VX2 liver tumor model. This may provide a potential basis for exploring the immune-related mechanisms of embolization in liver cancer. |
format | Online Article Text |
id | pubmed-8434853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84348532021-09-13 Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor Shi, Qin Li, Tongqiang Huang, Songjiang Bai, Yaowei Wang, Yingliang Liu, Jiacheng Zhou, Chen Chen, Yang Xiong, Bin Cancer Manag Res Original Research PURPOSE: To evaluate the effect and immune response of transcatheter arterial embolization (TAE) combined with donafenib in rabbit VX2 liver tumor model. MATERIALS AND METHODS: Thirty-six New Zealand white rabbits with VX2 liver tumor were randomly divided into three groups. The LD group was treated with the emulsion of 0.5 mL lipiodol and 4 mg donafenib via hepatic arterial administration. The LE group was treated with the emulsion of 0.5 mL lipiodol and 4 mg epirubicin. The control group was treated with the equal volume of saline. Four rabbits were euthanized in each group on day 1, 3 and 7 after treatment. The tumor growth, histological markers associated with angiogenesis and immune response were assessed by imaging and histopathology. In addition, immune modulatory cytokines included interleukin (IL)-6, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and biochemical hepatorenal function were measured. RESULTS: Compared to other groups, LD group achieved lower tumor growth rate, fewer metastatic lesions, and higher tumor necrosis rate on day 7 after treatment. The percentage of CD31-positive area in the LD group was significantly lower than that in the LE group on day 3 and 7 after treatment. In addition, CD8(+) lymphocytes infiltration was more pronounced in LD group than in LE group on day 7 after treatment, regardless of in the tumor or adjacent liver tissue. Serum cytokines including IL-6, TNF-α and IFN-γ were strongly upregulated in the LD group on day 1 after treatment. And there was no significant difference in the hepatorenal function between LD group and LE group after treatment. CONCLUSION: The combination of TAE and angiogenesis inhibitor donafenib resulted in a potentiated tumoricidal effect, anti-angiogenesis and antitumour T cell response in rabbit VX2 liver tumor model. This may provide a potential basis for exploring the immune-related mechanisms of embolization in liver cancer. Dove 2021-09-07 /pmc/articles/PMC8434853/ /pubmed/34522137 http://dx.doi.org/10.2147/CMAR.S328294 Text en © 2021 Shi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Shi, Qin Li, Tongqiang Huang, Songjiang Bai, Yaowei Wang, Yingliang Liu, Jiacheng Zhou, Chen Chen, Yang Xiong, Bin Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor |
title | Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor |
title_full | Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor |
title_fullStr | Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor |
title_full_unstemmed | Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor |
title_short | Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor |
title_sort | transcatheter arterial embolization containing donafenib induces anti-angiogenesis and tumoricidal cd8(+) t-cell infiltration in rabbit vx2 liver tumor |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434853/ https://www.ncbi.nlm.nih.gov/pubmed/34522137 http://dx.doi.org/10.2147/CMAR.S328294 |
work_keys_str_mv | AT shiqin transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT litongqiang transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT huangsongjiang transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT baiyaowei transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT wangyingliang transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT liujiacheng transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT zhouchen transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT chenyang transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor AT xiongbin transcatheterarterialembolizationcontainingdonafenibinducesantiangiogenesisandtumoricidalcd8tcellinfiltrationinrabbitvx2livertumor |